Erlotinib a nem kissejtes tüdorák kezelésében

Translated title of the contribution: Erlotinib in the treatment of non-small cell lung cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Because erlotinib, an epidermal growth factor receptor tyrosine kinase (EGFRTK) inhibitor, has been shown to be effective and well-tolerated as a second/third-line treatment in the therapy of advanced non-small cell lung cancer (NSCLC), this agent has been recently approved for human NSCLC therapy in the European Union. Although additive and synergistic effects of erlotinib and conventional chemotherapy were demonstrated in the combined regime preclinically, this has yet to be approved in the clinic. Since erlotinib and cytotoxic drugs have different biological targets, they have distinct side effects as well: erlotinib has no toxic effect on the bone marrow, but can cause diarrhea and rash, the latter being thought to be an indicator of the therapeutic efficacy. Several ongoing clinical trials are investigating the potential role of erlotinib in different settings in human NSCLC. This review intends to integrate our current knowledge on the erlotinib treatment in NSCLC.

Original languageHungarian
Pages (from-to)237-241
Number of pages5
JournalMagyar Onkologia
Volume50
Issue number3
Publication statusPublished - 2006

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Poisons
European Union
Exanthema
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Erlotinib Hydrochloride
Diarrhea
Bone Marrow
Clinical Trials
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Erlotinib a nem kissejtes tüdorák kezelésében. / Ostoros, G.; Döme, B.

In: Magyar Onkologia, Vol. 50, No. 3, 2006, p. 237-241.

Research output: Contribution to journalArticle

@article{b8d74e69aa6f4b50968d11d7e4e18f27,
title = "Erlotinib a nem kissejtes t{\"u}dor{\'a}k kezel{\'e}s{\'e}ben",
abstract = "Because erlotinib, an epidermal growth factor receptor tyrosine kinase (EGFRTK) inhibitor, has been shown to be effective and well-tolerated as a second/third-line treatment in the therapy of advanced non-small cell lung cancer (NSCLC), this agent has been recently approved for human NSCLC therapy in the European Union. Although additive and synergistic effects of erlotinib and conventional chemotherapy were demonstrated in the combined regime preclinically, this has yet to be approved in the clinic. Since erlotinib and cytotoxic drugs have different biological targets, they have distinct side effects as well: erlotinib has no toxic effect on the bone marrow, but can cause diarrhea and rash, the latter being thought to be an indicator of the therapeutic efficacy. Several ongoing clinical trials are investigating the potential role of erlotinib in different settings in human NSCLC. This review intends to integrate our current knowledge on the erlotinib treatment in NSCLC.",
author = "G. Ostoros and B. D{\"o}me",
year = "2006",
language = "Hungarian",
volume = "50",
pages = "237--241",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Erlotinib a nem kissejtes tüdorák kezelésében

AU - Ostoros, G.

AU - Döme, B.

PY - 2006

Y1 - 2006

N2 - Because erlotinib, an epidermal growth factor receptor tyrosine kinase (EGFRTK) inhibitor, has been shown to be effective and well-tolerated as a second/third-line treatment in the therapy of advanced non-small cell lung cancer (NSCLC), this agent has been recently approved for human NSCLC therapy in the European Union. Although additive and synergistic effects of erlotinib and conventional chemotherapy were demonstrated in the combined regime preclinically, this has yet to be approved in the clinic. Since erlotinib and cytotoxic drugs have different biological targets, they have distinct side effects as well: erlotinib has no toxic effect on the bone marrow, but can cause diarrhea and rash, the latter being thought to be an indicator of the therapeutic efficacy. Several ongoing clinical trials are investigating the potential role of erlotinib in different settings in human NSCLC. This review intends to integrate our current knowledge on the erlotinib treatment in NSCLC.

AB - Because erlotinib, an epidermal growth factor receptor tyrosine kinase (EGFRTK) inhibitor, has been shown to be effective and well-tolerated as a second/third-line treatment in the therapy of advanced non-small cell lung cancer (NSCLC), this agent has been recently approved for human NSCLC therapy in the European Union. Although additive and synergistic effects of erlotinib and conventional chemotherapy were demonstrated in the combined regime preclinically, this has yet to be approved in the clinic. Since erlotinib and cytotoxic drugs have different biological targets, they have distinct side effects as well: erlotinib has no toxic effect on the bone marrow, but can cause diarrhea and rash, the latter being thought to be an indicator of the therapeutic efficacy. Several ongoing clinical trials are investigating the potential role of erlotinib in different settings in human NSCLC. This review intends to integrate our current knowledge on the erlotinib treatment in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=34848911357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848911357&partnerID=8YFLogxK

M3 - Article

C2 - 17099784

AN - SCOPUS:34848911357

VL - 50

SP - 237

EP - 241

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -